Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.
Ontology highlight
ABSTRACT: Cystic fibrosis (CF) is caused by mutations in the CF transmembrane regulator (CFTR) that result in reduced anion conductance at the apical membrane of secretory epithelia. Treatment of CF patients carrying the G551D gating mutation with the potentiator VX-770 (ivacaftor) largely restores channel activity and has shown substantial clinical benefit. However, most CF patients carry the ΔF508 mutation, which impairs CFTR folding, processing, function, and stability. Studies in homozygous ΔF508 CF patients indicated little clinical benefit of monotherapy with the investigational corrector VX-809 (lumacaftor) or VX-770, whereas combination clinical trials show limited but significant improvements in lung function. We show that VX-770, as well as most other potentiators, reduces the correction e
SUBMITTER: Veit G
PROVIDER: S-EPMC4467693 | biostudies-literature | 2014 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA